Insulin receptor substrate 1 explained

Insulin receptor substrate 1 (IRS-1) is a signaling adapter protein that in humans is encoded by the IRS1 gene.[1] It is a 131 kDa protein with amino acid sequence of 1242 residues.[2] It contains a single pleckstrin homology (PH) domain at the N-terminus and a PTB domain ca. 40 residues downstream of this, followed by a poorly conserved C-terminus tail.[3] Together with IRS2, IRS3 (pseudogene) and IRS4, it is homologous to the Drosophila protein chico, whose disruption extends the median lifespan of flies up to 48%.[4] Similarly, Irs1 mutant mice experience moderate life extension and delayed age-related pathologies.[5]

Function

Insulin receptor substrate 1 plays a key role in transmitting signals from the insulin receptor (IR) and insulin-like growth factor 1 receptor (IGF-1) to intracellular pathways PI3K / Akt and Erk MAP kinase pathways. Tyrosine phosphorylation of IRS-1 by insulin receptor (IR) introduces multiple binding sites for proteins bearing SH2 homology domain, such as PI3K, Grb-2/Sos complex and SHP2. PI3K, involved in interaction with IRS-1, produces PIP3, which, in turn, recruits Akt kinase. Further, Akt kinase is activated via phosphorylation of its T308 residue and analogous sites in PKC by PDK1. This phosphorylation is absent in tissues lacking IRS-1. The cascade is followed by glucose uptake. Formation of the Grb-2/Sos complex, also known as the RAS guanine nucleotide exchange factor complex, results in ERK1/2 activation. IRS-1 signal transduction may be inhibited by SHP2 in some tissues.

Tyrosine phosphorylation of the insulin receptors or IGF-1 receptors, upon extracellular ligand binding, induces the cytoplasmic binding of IRS-1 to these receptors, through its PTB domains. Multiple tyrosine residues of IRS-1 itself are then phosphorylated by these receptors. This enables IRS-1 to activate several signalling pathways, including the PI3K pathway and the MAP kinase pathway.

An alternative multi-site phosphorylation of Serine/Threonine in IRS-1 regulates insulin signaling positively and negatively. C-terminal region contains most of the phosphorylation sites of the protein. The C-terminal tail is not structured, therefore the mechanisms of regulation of IRS-1 by phosphorylation still remain unclear. It has been shown that TNFα causes insulin resistance and multi-site S/T phosphorylation, which results in block of interaction between IRS-1 and juxtamembrane domain peptide, thus converting IRS-1 into an inactive state.

IRS-1 plays important biological function for both metabolic and mitogenic (growth promoting) pathways: mice deficient of IRS1 have only a mild diabetic phenotype, but a pronounced growth impairment, i.e., IRS-1 knockout mice only reach 50% of the weight of normal mice.

Regulation

The cellular protein levels of IRS-1 are regulated by the Cullin-7 E3 ubiquitin ligase, which targets IRS-1 for ubiquitin mediated degradation by the proteasome.[6] Different Serine phosphorylation of IRS-1, caused by various molecules, such as fatty acids, TNFα and AMPK, has different effects on the protein, but most of these effects include cellular re-localization, conformational and steric changes. These processes lead to decrease in Tyrosine phosphorylation by insulin receptors and diminished PI3K recruitment. Altogether, these mechanisms stimulate IRS-1 degradation and insulin resistance. Other inhibitory pathways include SOCS proteins and O-GlcNAcylation of IRS-1. SOCS proteins act by binding to IR and by interfering with IR phosphorylation of IRS-1, therefore attenuating insulin signaling. They can also bind to JAK, causing a subsequent decrease in IRS-1 tyrosine phosphorylation. During insulin resistance induced by hyperglycemia, glucose accumulates in tissues as its hexosamine metabolite UDP-GlcNAc. This metabolite if present in high amounts leads to O-GlcNAc protein modifications. IRS-1 can undergo this modification, which results in its phosphorylation and functional suppression.[7]

Interactions

IRS1 has been shown to interact (also concerted activity) with:

Role in cancer

IRS-1, as a signalling adapter protein, is able to integrate different signalling cascades, which indicates its possible role in cancer progression.[32] IRS-1 protein is known to be involved in various types of cancer, including colorectal,[33] lung,[34] prostate and breast cancer.[35] IRS-1 integrates signalling from insulin receptor (InsR), insulin-like growth factor-1 receptor (IGF1R) and many other cytokine receptors and is elevated in β-catenin induced cells. Some evidence shows that TCF/LEF-β-catenin complexes directly regulate IRS-1. IRS-1 is required for maintenance of neoplasmic phenotype in adenomatous polyposis coli (APC) - mutated cells, it is also needed for transformation in ectopically expressing oncogenic β-catenin cells. IRS-1 dominant-negative mutant functions as tumor suppressor, whereas ectopic IRS-1 stimulates oncogenic transformation. IRS-1 is upregulated in colorectal cancers (CRC) with elevated levels of β-catenin, c-MYC, InsRβ and IGF1R. IRS-1 promotes CRC metastasis to the liver. Decreased apoptosis of crypt stem cells is associated with colon cancer risk. Reduced expression of IRS-1 in Apc (min/+) mutated mice shows increased irradiation-induced apoptosis in crypt. Deficiency in IRS-1 - partial (+/-) or absolute (-/-) - in Apc (min/+) mice demonstrates reduced amount of tumors comparing to IRS-1 (+/+)/ Apc (min/+) mice.[36]

In lung adenocarcinoma cell line A549 overexpression of IRS-1 leads to reduced growth. Tumor infiltrating neutrophils have recently been thought to adjust tumor growth and invasiveness. Neutrophil elastase is shown to degrade IRS-1 by gaining access to endosomal compartment of carcinoma cell. IRS-1 degradation induces cell proliferation in mouse and human adenocarcinomas. Ablation of IRS-1 alters downstream signalling through phosphatidylinositol-3 kinase (PI3K), causing an increased interaction of it with platelet-derived growth factor receptor (PDGFR). Therefore, IRS-1 acts as major regulator of PI3K in lung adenocarcinoma.[34]

Some evidence shows role of IRS-1 in hepatocellular carcinoma (HCC). In rat model, IRS-1 focal overexpression is associated with early events of hepatocarcinogenesis. During progression of preneoplastic foci into hepatocellular carcinomas expression of IRS-1 gradually decreases, which is characterises a metabolic shift heading towards malignant neoplastic phenotype.[37] Transgenic mice, co-expressing IRS-1 and hepatitis Bx (HBx) protein, demonstrate higher rate of hepatocellular displasia that results in HCC development. Expressed alone, IRS-1 and HBx are not sufficient to induce neoplastic alterations in the liver, though their paired expression switches on IN/IRS-1/MAPK and Wnt/β-catenin cascades, causing HCC transformation.[38]

LNCaP prostate cancer cells increase cell adhesion and diminish cell motility via IGF-1 independent mechanism, when IRS-1 is ectopically expressed in the cells. These effects are mediated by PI3K. Uncanonical phosphorylation of Serine 612 by PI3K of IRS-1 protein is due to hyper-activation of Akt/PKB pathway in LNCaP. IRS-1 interacts with integrin α5β1, activating an alternative signalling cascade. This cascade results in decreased cell motility opposing to IGF-1 - dependent mechanism. Loss of IRS-1 expression and PTEN mutations in LNCaP cells could promote metastasis.[39] Ex vivo studies of IRS-1 involvement in prostate cancer show ambiguous results. Down-regulation of IGF1R in bone marrow biopsies of metastatic prostate cancer goes along with down-regulation of IRS-1 and significant reduction of PTEN in 3 out of 12 cases. Most of the tumors still express IRS-1 and IGF1R during progression of the metastatic disease.[40]

IRS-1 has a functional role in breast cancer progression and metastasis. Overexpression of PTEN in MCF-7 epithelial breast cancer cells inhibits cell growth by inhibiting MAPK pathway. ERK phosphorylation through IRS-1/Grb-2/Sos pathway is inhibited by phosphatase activity of PTEN. PTEN does not have effect on IRS-1 independent MAPK activation. When treated with insulin, ectopic expression of PTEN in MCF-7 suppresses IRS-1/Grb-2/Sos complex formation due to differential phosphorylation of IRS-1.[41] Overexpression of IRS-1 has been linked to antiestrogen resistance and hormone independence in breast cancer. Tamoxifen (TAM) inhibits IRS-1 function, therefore suppressing IRS-1/PI3K signalling cascade in estrogen receptor positive (ER+) MCF-7 cell line. IRS-1 siRNA is able to reduce IRS-1 transcript level, thereby reducing protein expression in MCF-7 ER+ cells. Reduction of IRS-1 leads to decreased survival of these cells. siRNA treatment effects are additive to effects of TAM treatment.[42] IGFRs and estrogen coaction facilitates growth in different breast cancer cell lines, however amplification of IGF1R signalling can abrogate need of estrogen for transformation and growth of MCF-7 cells. IRS-1 overexpression in breast cancer cells decreased estrogen requirements. This decrease is dependent on IRS-1 levels in the cells.[43] Estradiol enhances expression of IRS-1 and activity of ERK1/2 and PI3K/Akt pathways in MCF-7 and CHO cells transfected with mouse IRS-1 promoter. Estradiol acts directly on IRS-1 regulatory sequences and positively regulates IRS-1 mRNA production.[44] Decreased anchorage- dependent/independent cell growth and initiation of cell death under low growth factor and estrogen conditions are observed in MCF-7 cells with down-regulated IRS-1.[45] mir126 is underexpressed in breast cancer cells. mir126 targets IRS-1 at transcriptional level and inhibits transition from G1/G0 phase to S phase during cell cycle in HEK293 and MCF-7 cells.[46] Transgenic mice overexpressing IRS-1 develop metastatic breast cancer. The tumors demonstrate squamous differentiation which is associated with β-catenin pathway. IRS-1 interacts with β-catenin both in vitro and in vivo.[47] IRS-1 and its homologue IRS-2 play distinct roles in breast cancer progression and metastasis. Overexpression of either one is sufficient to cause tumorogenesis in vivo. Frequency of lung metastasis in IRS-1 deficient tumor is elevated opposing to IRS-2 deficient tumor, where it is decreased. Basically, IRS-2 has a positive impact on metastasis of breast cancer whereas a stronger metastatic potential is observed when IRS-1 is down-regulated. IRS-1 is strongly expressed in ductal carcinoma in situ, when IRS-2 is elevated in invasive tumors. Increased IRS-1 makes MCF-7 cells susceptible to specific chemotherapeutic agents, such as taxol, etoposide, and vincristine. Therefore, IRS-1 can be a good pointer of specific drug therapies effectiveness for breast cancer treatment.[48]

Further reading

Notes and References

  1. Sun XJ, Rothenberg P, Kahn CR, Backer JM, Araki E, Wilden PA, Cahill DA, Goldstein BJ, White MF . Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein . Nature . 352 . 6330 . 73–7 . July 1991 . 1648180 . 10.1038/352073a0 . 1991Natur.352...73S . 4311960 .
  2. Web site: IRS1 - Insulin receptor substrate 1 - Homo sapiens (Human) - IRS1 gene & protein. www.uniprot.org. 2016-04-21.
  3. Copps KD, White MF . Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2 . Diabetologia . 55 . 10 . 2565–82 . October 2012 . 22869320 . 4011499 . 10.1007/s00125-012-2644-8 .
  4. Clancy DJ, Gems D, Harshman LG, Oldham S, Stocker H, Hafen E, Leevers SJ, Partridge L . Extension of life-span by loss of CHICO, a Drosophila insulin receptor substrate protein . Science . 292 . 5514 . 104–6 . April 2001 . 11292874 . 10.1126/science.1057991 . 2001Sci...292..104C . 30331471 .
  5. Selman C, Lingard S, Choudhury AI, Batterham RL, Claret M, Clements M, Ramadani F, Okkenhaug K, Schuster E, Blanc E, Piper MD, Al-Qassab H, Speakman JR, Carmignac D, Robinson IC, Thornton JM, Gems D, Partridge L, Withers DJ . Evidence for lifespan extension and delayed age-related biomarkers in insulin receptor substrate 1 null mice . FASEB Journal . 22 . 3 . 807–18 . March 2008 . 17928362 . 10.1096/fj.07-9261com . free . 12387212 .
  6. Xu X, Sarikas A, Dias-Santagata DC, Dolios G, Lafontant PJ, Tsai SC, Zhu W, Nakajima H, Nakajima HO, Field LJ, Wang R, Pan ZQ . The CUL7 E3 ubiquitin ligase targets insulin receptor substrate 1 for ubiquitin-dependent degradation . Molecular Cell . 30 . 4 . 403–14 . May 2008 . 18498745 . 2633441 . 10.1016/j.molcel.2008.03.009 .
  7. Gual P, Le Marchand-Brustel Y, Tanti JF . Positive and negative regulation of insulin signaling through IRS-1 phosphorylation . Biochimie . 87 . 1 . 99–109 . January 2005 . 15733744 . 10.1016/j.biochi.2004.10.019 .
  8. Ueno H, Kondo E, Yamamoto-Honda R, Tobe K, Nakamoto T, Sasaki K, Mitani K, Furusaka A, Tanaka T, Tsujimoto Y, Kadowaki T, Hirai H . Association of insulin receptor substrate proteins with Bcl-2 and their effects on its phosphorylation and antiapoptotic function . Molecular Biology of the Cell . 11 . 2 . 735–46 . February 2000 . 10679027 . 14806 . 10.1091/mbc.11.2.735 .
  9. Skolnik EY, Lee CH, Batzer A, Vicentini LM, Zhou M, Daly R, Myers MJ, Backer JM, Ullrich A, White MF . The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signalling . The EMBO Journal . 12 . 5 . 1929–36 . May 1993 . 8491186 . 413414 . 10.1002/j.1460-2075.1993.tb05842.x.
  10. Morrison KB, Tognon CE, Garnett MJ, Deal C, Sorensen PH . ETV6-NTRK3 transformation requires insulin-like growth factor 1 receptor signaling and is associated with constitutive IRS-1 tyrosine phosphorylation . Oncogene . 21 . 37 . 5684–95 . August 2002 . 12173038 . 10.1038/sj.onc.1205669 . 2899858 .
  11. Giorgetti-Peraldi S, Peyrade F, Baron V, Van Obberghen E . Involvement of Janus kinases in the insulin signaling pathway . European Journal of Biochemistry . 234 . 2 . 656–60 . December 1995 . 8536716 . 10.1111/j.1432-1033.1995.656_b.x . free .
  12. Sawka-Verhelle D, Tartare-Deckert S, White MF, Van Obberghen E . Insulin receptor substrate-2 binds to the insulin receptor through its phosphotyrosine-binding domain and through a newly identified domain comprising amino acids 591-786 . The Journal of Biological Chemistry . 271 . 11 . 5980–3 . March 1996 . 8626379 . 10.1074/jbc.271.11.5980 . free.
  13. Tartare-Deckert S, Sawka-Verhelle D, Murdaca J, Van Obberghen E . Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system . The Journal of Biological Chemistry . 270 . 40 . 23456–60 . October 1995 . 7559507 . 10.1074/jbc.270.40.23456 . free .
  14. Dey BR, Frick K, Lopaczynski W, Nissley SP, Furlanetto RW . Evidence for the direct interaction of the insulin-like growth factor I receptor with IRS-1, Shc, and Grb10 . Molecular Endocrinology . 10 . 6 . 631–41 . June 1996 . 8776723 . 10.1210/mend.10.6.8776723 . free .
  15. Mañes S, Mira E, Gómez-Mouton C, Zhao ZJ, Lacalle RA, Martínez-A C . Concerted activity of tyrosine phosphatase SHP-2 and focal adhesion kinase in regulation of cell motility . Molecular and Cellular Biology . 19 . 4 . 3125–35 . April 1999 . 10082579 . 84106 . 10.1128/mcb.19.4.3125 .
  16. Johnston JA, Wang LM, Hanson EP, Sun XJ, White MF, Oakes SA, Pierce JH, O'Shea JJ . Interleukins 2, 4, 7, and 15 stimulate tyrosine phosphorylation of insulin receptor substrates 1 and 2 in T cells. Potential role of JAK kinases . The Journal of Biological Chemistry . 270 . 48 . 28527–30 . December 1995 . 7499365 . 10.1074/jbc.270.48.28527 . free .
  17. Gual P, Baron V, Lequoy V, Van Obberghen E . Interaction of Janus kinases JAK-1 and JAK-2 with the insulin receptor and the insulin-like growth factor-1 receptor . Endocrinology . 139 . 3 . 884–93 . March 1998 . 9492017 . 10.1210/endo.139.3.5829 . free .
  18. Kawazoe Y, Naka T, Fujimoto M, Kohzaki H, Morita Y, Narazaki M, Okumura K, Saitoh H, Nakagawa R, Uchiyama Y, Akira S, Kishimoto T . Signal transducer and activator of transcription (STAT)-induced STAT inhibitor 1 (SSI-1)/suppressor of cytokine signaling 1 (SOCS1) inhibits insulin signal transduction pathway through modulating insulin receptor substrate 1 (IRS-1) phosphorylation . The Journal of Experimental Medicine . 193 . 2 . 263–9 . January 2001 . 11208867 . 2193341 . 10.1084/jem.193.2.263 .
  19. Aguirre V, Werner ED, Giraud J, Lee YH, Shoelson SE, White MF . Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action . The Journal of Biological Chemistry . 277 . 2 . 1531–7 . January 2002 . 11606564 . 10.1074/jbc.M101521200 . free .
  20. Aguirre V, Uchida T, Yenush L, Davis R, White MF . The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307) . The Journal of Biological Chemistry . 275 . 12 . 9047–54 . March 2000 . 10722755 . 10.1074/jbc.275.12.9047 . free .
  21. Hadari YR, Tzahar E, Nadiv O, Rothenberg P, Roberts CT, LeRoith D, Yarden Y, Zick Y . Insulin and insulinomimetic agents induce activation of phosphatidylinositol 3'-kinase upon its association with pp185 (IRS-1) in intact rat livers . The Journal of Biological Chemistry . 267 . 25 . 17483–6 . September 1992 . 10.1016/S0021-9258(19)37065-6 . 1381348 . free .
  22. Gual P, Gonzalez T, Grémeaux T, Barres R, Le Marchand-Brustel Y, Tanti JF . Hyperosmotic stress inhibits insulin receptor substrate-1 function by distinct mechanisms in 3T3-L1 adipocytes . The Journal of Biological Chemistry . 278 . 29 . 26550–7 . July 2003 . 12730242 . 10.1074/jbc.M212273200 . free .
  23. Hamer I, Foti M, Emkey R, Cordier-Bussat M, Philippe J, De Meyts P, Maeder C, Kahn CR, Carpentier JL . An arginine to cysteine(252) mutation in insulin receptors from a patient with severe insulin resistance inhibits receptor internalisation but preserves signalling events . Diabetologia . 45 . 5 . 657–67 . May 2002 . 12107746 . 10.1007/s00125-002-0798-5 . free .
  24. Xia X, Serrero G . Multiple forms of p55PIK, a regulatory subunit of phosphoinositide 3-kinase, are generated by alternative initiation of translation . The Biochemical Journal . 341 . 3 . 831–7 . August 1999 . 10417350 . 1220424 . 10.1042/0264-6021:3410831 .
  25. Mothe I, Delahaye L, Filloux C, Pons S, White MF, Van Obberghen E . Interaction of wild type and dominant-negative p55PIK regulatory subunit of phosphatidylinositol 3-kinase with insulin-like growth factor-1 signaling proteins . Molecular Endocrinology . 11 . 13 . 1911–23 . December 1997 . 9415396 . 10.1210/mend.11.13.0029 . free .
  26. Lebrun P, Mothe-Satney I, Delahaye L, Van Obberghen E, Baron V . Insulin receptor substrate-1 as a signaling molecule for focal adhesion kinase pp125(FAK) and pp60(src) . The Journal of Biological Chemistry . 273 . 48 . 32244–53 . November 1998 . 9822703 . 10.1074/jbc.273.48.32244 . free .
  27. Kuhné MR, Pawson T, Lienhard GE, Feng GS . The insulin receptor substrate 1 associates with the SH2-containing phosphotyrosine phosphatase Syp . The Journal of Biological Chemistry . 268 . 16 . 11479–81 . June 1993 . 10.1016/S0021-9258(19)50220-4 . 8505282 . free .
  28. Myers MG, Mendez R, Shi P, Pierce JH, Rhoads R, White MF . The COOH-terminal tyrosine phosphorylation sites on IRS-1 bind SHP-2 and negatively regulate insulin signaling . The Journal of Biological Chemistry . 273 . 41 . 26908–14 . October 1998 . 9756938 . 10.1074/jbc.273.41.26908 . free .
  29. Goldstein BJ, Bittner-Kowalczyk A, White MF, Harbeck M . Tyrosine dephosphorylation and deactivation of insulin receptor substrate-1 by protein-tyrosine phosphatase 1B. Possible facilitation by the formation of a ternary complex with the Grb2 adaptor protein . The Journal of Biological Chemistry . 275 . 6 . 4283–9 . February 2000 . 10660596 . 10.1074/jbc.275.6.4283 . free .
  30. Ravichandran LV, Chen H, Li Y, Quon MJ . Phosphorylation of PTP1B at Ser(50) by Akt impairs its ability to dephosphorylate the insulin receptor . Molecular Endocrinology . 15 . 10 . 1768–80 . October 2001 . 11579209 . 10.1210/mend.15.10.0711 . free .
  31. Craparo A, Freund R, Gustafson TA . 14-3-3 (epsilon) interacts with the insulin-like growth factor I receptor and insulin receptor substrate I in a phosphoserine-dependent manner . The Journal of Biological Chemistry . 272 . 17 . 11663–9 . April 1997 . 9111084 . 10.1074/jbc.272.17.11663 . free .
  32. Dearth RK, Cui X, Kim HJ, Hadsell DL, Lee AV . Oncogenic transformation by the signaling adaptor proteins insulin receptor substrate (IRS)-1 and IRS-2 . Cell Cycle . 6 . 6 . 705–13 . March 2007 . 17374994 . 10.4161/cc.6.6.4035 . free .
  33. Esposito DL, Aru F, Lattanzio R, Morgano A, Abbondanza M, Malekzadeh R, Bishehsari F, Valanzano R, Russo A, Piantelli M, Moschetta A, Lotti LV, Mariani-Costantini R . The insulin receptor substrate 1 (IRS1) in intestinal epithelial differentiation and in colorectal cancer . PLOS ONE . 7 . 4 . e36190 . 2012-04-27 . 22558377 . 3338610 . 10.1371/journal.pone.0036190 . 2012PLoSO...736190E . free .
  34. Houghton AM, Rzymkiewicz DM, Ji H, Gregory AD, Egea EE, Metz HE, Stolz DB, Land SR, Marconcini LA, Kliment CR, Jenkins KM, Beaulieu KA, Mouded M, Frank SJ, Wong KK, Shapiro SD . Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth . Nature Medicine . 16 . 2 . 219–23 . February 2010 . 20081861 . 2821801 . 10.1038/nm.2084 .
  35. Gibson SL, Ma Z, Shaw LM . Divergent roles for IRS-1 and IRS-2 in breast cancer metastasis . Cell Cycle . 6 . 6 . 631–7 . March 2007 . 17361103 . 10.4161/cc.6.6.3987 . free .
  36. Ramocki NM, Wilkins HR, Magness ST, Simmons JG, Scull BP, Lee GH, McNaughton KK, Lund PK . Insulin receptor substrate-1 deficiency promotes apoptosis in the putative intestinal crypt stem cell region, limits Apcmin/+ tumors, and regulates Sox9 . Endocrinology . 149 . 1 . 261–7 . January 2008 . 17916629 . 2194604 . 10.1210/en.2007-0869 .
  37. Nehrbass D, Klimek F, Bannasch P . Overexpression of insulin receptor substrate-1 emerges early in hepatocarcinogenesis and elicits preneoplastic hepatic glycogenosis . The American Journal of Pathology . 152 . 2 . 341–5 . February 1998 . 9466558 . 1857952 .
  38. Longato L, de la Monte S, Kuzushita N, Horimoto M, Rogers AB, Slagle BL, Wands JR . Overexpression of insulin receptor substrate-1 and hepatitis Bx genes causes premalignant alterations in the liver . Hepatology . 49 . 6 . 1935–43 . June 2009 . 19475691 . 2754284 . 10.1002/hep.22856 .
  39. Reiss K, Wang JY, Romano G, Tu X, Peruzzi F, Baserga R . Mechanisms of regulation of cell adhesion and motility by insulin receptor substrate-1 in prostate cancer cells . Oncogene . 20 . 4 . 490–500 . January 2001 . 11313980 . 10.1038/sj.onc.1204112 . 19294187 .
  40. Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay VM . Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease . Cancer Research . 62 . 10 . 2942–50 . May 2002 . 12019176 .
  41. Weng LP, Smith WM, Brown JL, Eng C . PTEN inhibits insulin-stimulated MEK/MAPK activation and cell growth by blocking IRS-1 phosphorylation and IRS-1/Grb-2/Sos complex formation in a breast cancer model . Human Molecular Genetics . 10 . 6 . 605–16 . March 2001 . 11230180 . 10.1093/hmg/10.6.605 . free .
  42. Cesarone G, Edupuganti OP, Chen CP, Wickstrom E . Insulin receptor substrate 1 knockdown in human MCF7 ER+ breast cancer cells by nuclease-resistant IRS1 siRNA conjugated to a disulfide-bridged D-peptide analogue of insulin-like growth factor 1 . Bioconjugate Chemistry . 18 . 6 . 1831–40 . 2007-12-01 . 17922544 . 10.1021/bc070135v .
  43. Surmacz E, Burgaud JL . Overexpression of insulin receptor substrate 1 (IRS-1) in the human breast cancer cell line MCF-7 induces loss of estrogen requirements for growth and transformation . Clinical Cancer Research . 1 . 11 . 1429–36 . November 1995 . 9815941 .
  44. Mauro L, Salerno M, Panno ML, Bellizzi D, Sisci D, Miglietta A, Surmacz E, Andò S . Estradiol increases IRS-1 gene expression and insulin signaling in breast cancer cells . Biochemical and Biophysical Research Communications . 288 . 3 . 685–9 . November 2001 . 11676497 . 10.1006/bbrc.2001.5815 .
  45. Nolan MK, Jankowska L, Prisco M, Xu S, Guvakova MA, Surmacz E . Differential roles of IRS-1 and SHC signaling pathways in breast cancer cells . International Journal of Cancer . 72 . 5 . 828–34 . September 1997 . 9311601 . 10.1002/(sici)1097-0215(19970904)72:5<828::aid-ijc20>3.0.co;2-3. 8237080 .
  46. Zhang J, Du YY, Lin YF, Chen YT, Yang L, Wang HJ, Ma D . The cell growth suppressor, mir-126, targets IRS-1 . Biochemical and Biophysical Research Communications . 377 . 1 . 136–40 . December 2008 . 18834857 . 10.1016/j.bbrc.2008.09.089 .
  47. Dearth RK, Cui X, Kim HJ, Kuiatse I, Lawrence NA, Zhang X, Divisova J, Britton OL, Mohsin S, Allred DC, Hadsell DL, Lee AV . Mammary tumorigenesis and metastasis caused by overexpression of insulin receptor substrate 1 (IRS-1) or IRS-2 . Molecular and Cellular Biology . 26 . 24 . 9302–14 . December 2006 . 17030631 . 1698542 . 10.1128/MCB.00260-06 .
  48. Porter HA, Perry A, Kingsley C, Tran NL, Keegan AD . IRS1 is highly expressed in localized breast tumors and regulates the sensitivity of breast cancer cells to chemotherapy, while IRS2 is highly expressed in invasive breast tumors . Cancer Letters . 338 . 2 . 239–48 . September 2013 . 23562473 . 3761875 . 10.1016/j.canlet.2013.03.030 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Insulin receptor substrate 1".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.